A 37-year-old man with ankylosing spondylitis (AS) and psoriasis who was successfully treated with methotrexate (MTX) is reported. In 1980, he had low back pain, limited motion in the lumbar spine, radiological findings of bilateral sacroiliitis, and HLA-B27positivity. In January 1991, he developed psoriasis and he had difficulty in performing desk work in spite of treatment with antirheumatic drugs. In May 1991, MTX7.5 mg/week per os was started. Joint symptoms, psoriasis, and acute phase reactants improved within 1 month after the treatment and this improvement continued for more than 6 months after the treatment. After discharge he was able to return to his job. (Internal Medicine 32: 53-56, 1993) 
Introduction
Ankylosing spondylitis (AS) is defined as the formation of a stiff joint by consolidation of the articulating surfaces and inflammation of the vertebral column; the most characteristic lesion in AS is sacroiliitis (1) . The majority of patients with AS have chronic discomfort over manyyears and they are refractory to treatment with various antiinflammatory drugs although it is in relatively few patients that the disease progresses to severe and total ankylosis (2) . Wereport a patient with ASwhose quality of average daily living was so disturbed that he could not perform desk work, however he was able to return to his job after successful treatment with methotrexate (MTX).
Case Report
In April 1991, a 37-year-old male patient was admitted He gradually became unable to perform his desk work and was readmitted in April 1991. From January 1991, he had noticed mild infiltrative skin lesions in the occiput, right buttock, and left foot, the biopsy of which was diagnosed as psoriasis.
Cervical and inguinal lymph nodes were enlarged at the time of readmission.
This lymphadenopathy was considered to be associated with psoriasis since it appeared after the onset of psoriasis. There was tenderness in the cervical and lumbar spine, both shoulder joints, He assumed a leaning posture and was unable to keep an upright posture or to rise from bed. There was marked generalized muscle atrophy. Hemoglobin was 9.4g/dl, platelet counts were 58 x lO4/^, ESR was 78mm/hr, CRP was 9.2mg/dl. continued for more than 6 months after the start of treatment. After discharge from the hospital he was able to return to his previous job. Table 1 shows the improvementof motionof the spine at 7 weeksafter the start of treatment with MTX. The occipit to wall distance decreased from 6 cm to 1.5 cm and finger to floor distance decreased from 68 cm to 35 cm. Chest expansion increased Ankylosing Spondylitis and Methotrexate absence of rheumatoid factor and subcutaneous nodules and 2) axial radiographs showing sacroiliitis. In fact, both of these characteristics are commonto those of AS. The present patient had no peripheral arthropathy characteristic of psoriatic arthritis. Taken together, we consider that our patient had AS coexisting with psoriasis.
Thus, the sacroiliitis seen in our patient maybe due to AS. That spinal arthropathy preceded the development of psoriasis by ll years may also favor the diagnosis of AScoexisting with psoriasis, although in some cases of psoriatic arthritis, up to 15 to 20 percent, psoriasis may follow arthritis (4). Thus we cannot exclude the possibility that our patient had psoriatic spondylitis concomitant with AS, since 1) current clinical problems appeared concurrently with the onset of psoriasis, and 2) peripheral arthropathy is not commonin psoriatic spondylitis. NSAIDs represent the mainstay of treatment in AS. However, NSAIDsare frequently discontinued primarily because of adverse reactions or lack of efficacy (6).
The search for more effective disease-modifying agents in AS has continued. Few studies are available showing the results of trials of the older slow-acting agents in AS. Gold has not been effective and the effect of auranofin remains to be elucidated. Penicillamine failed to produce significant improvement in one 6-month placebo-controlled study (7) . Sulfasalazine has been suggested to be effective (8-ll) . Wetreated our patient with auranofin and sulfasalazine and these drugs showed no effect. Finally MTXwas used with a dramatic beneficial effect. Recently, favorable results using MTXin the treatment of patients with AS have been reported (12, 13) . This is the first report of a Japanese patient with ASwho showed a favorable response to MTXtreatment. In the treatment of RA, it has been postulated that the quick clinical response after
MTXtherapy and the return of clinical activity after discontinuation of MTXare more consistent with the antiinflammatory action than immunosuppression (14) . The observations of the clinical course of the present patient seem to support this notion.
Since our patient had AScoexisting with psoriasis and 
